Skip to main content
Jyong Biotech Ltd. logo

Jyong Biotech Ltd. - Investor Relations & Filings

Listed IPO Jun 2025
Ticker · MENS ISIN · KYG831161065 US Manufacturing
Open in API
Filings indexed 64 across all filing types
Latest filing 2025-03-28 Regulatory Filings
Country US United States of America
Listing US MENS · 3 venues

About Jyong Biotech Ltd.

https://jyongbio.com/

Jyong Biotech Ltd. is a science-driven biotechnology company focused on the development and commercialization of plant-derived drugs for urinary system diseases. The company's primary therapeutic areas include benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Its lead drug candidate, MCS-2, is a botanical formulation that has completed late-stage (Phase III) clinical trials. Leveraging a proprietary research and development platform, Jyong Biotech aims to advance its pipeline of innovative botanical medicines to address unmet medical needs in urology for a global patient population.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings Classification · 95% confidence The document is a letter from Jyong Biotech Ltd. to the SEC requesting acceleration of the effective date of a Registration Statement on Form F-1. It references Rule 461 under the Securities Act of 1933 and requests confirmation of the effective time and date of the Registration Statement. The document is short (1772 characters) and is a formal request related to a registration filing, not the filing itself. It does not contain financial data or report content but is a procedural communication regarding the registration process. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-03-28 English
FREE WRITING PROSPECTUS
Capital/Financing Update Classification · 100% confidence The document is titled 'Issuer Free Writing Prospectus' and is filed pursuant to Rule 433 of the Securities Act of 1933. It relates to a Preliminary Prospectus dated March 11, 2025, and includes detailed information about an Initial Public Offering (IPO) by Jyong Biotech Ltd. The content includes offering summary, use of proceeds, lock-up agreements, company overview, industry overview, investment highlights, and other information typical of offering materials. It is not a financial report, earnings release, or management discussion, but rather a prospectus-type document used in capital raising. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities such as IPOs and offerings.
2025-03-27 English
FREE WRITING PROSPECTUS
Capital/Financing Update Classification · 95% confidence The document is titled 'Issuer Free Writing Prospectus' and is filed pursuant to Rule 433 of the Securities Act of 1933. It relates to a Preliminary Prospectus dated March 11, 2025, and includes detailed information about an Initial Public Offering (IPO) by Jyong Biotech Ltd. The content includes offering summary, use of proceeds, company overview, industry overview, investment highlights, and other information typical of a prospectus or offering document. This is not a financial report, earnings release, or management discussion, but rather a document related to capital raising and securities offering. Therefore, the document fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2025-03-26 English
REGISTRATION STATEMENT
Capital/Financing Update Classification · 95% confidence The document is a Form F-1/A Registration Statement filed with the SEC, dated March 11, 2025, for Jyong Biotech Ltd. It is an amendment to a registration statement under the Securities Act of 1933, used for initial public offerings (IPOs). The text includes detailed information about the offering, company structure, regulatory environment, and risk factors. This type of filing is a registration statement for securities offering, which is a capital raising document. It is not an annual or quarterly report, audit report, earnings release, or any other type of report listed. It is specifically a registration statement related to capital raising and securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement text, not just an announcement or notice, so it is not RPA or RNS. Confidence is high given the clear identification of the form and content.
2025-03-11 English
FREE WRITING PROSPECTUS
Capital/Financing Update Classification · 95% confidence The document is titled 'Free Writing Prospectus' and is filed pursuant to Rule 433 of the Securities Act of 1933. It relates to a Preliminary Prospectus dated February 6, 2025, for Jyong Biotech Ltd. The content includes detailed information about the company's business, drug candidates, market overview, use of proceeds, offering details, and disclaimers typical of a prospectus used in securities offerings. There is no indication that this is a full annual report, earnings release, or other regulatory filing type. Instead, it is a disclosure document related to a securities offering, specifically a Free Writing Prospectus, which is a type of offering document used in capital markets to provide additional information to investors beyond the preliminary prospectus. According to the filing definitions, updates on company fundraising or financing activities fall under 'Capital/Financing Update (CAP)'. Since this document is related to an initial public offering and contains detailed offering information, it fits best under the Capital/Financing Update category.
2025-02-18 English
FREE WRITING PROSPECTUS
Capital/Financing Update Classification · 95% confidence The document is titled 'Free Writing Prospectus' and is filed pursuant to Rule 433 of the Securities Act of 1933. It relates to a Preliminary Prospectus dated February 6, 2025, and includes detailed information about an initial public offering (IPO) by Jyong Biotech Ltd. The content includes offering summary, use of proceeds, lock-up agreements, company overview, industry overview, investment highlights, and financials. This type of document is a prospectus or offering document used in capital raising activities, specifically related to securities issuance. It is not a financial report, earnings release, management discussion, or regulatory filing unrelated to capital raising. Therefore, the document fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2025-02-07 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.